NEW YORK, Nov. 5-CuraGen will use its functional genomics techniques to validate and characterize drug targets for schizophrenia for Mitsubishi Pharma Corporation, the two companies said today.
CuraGen will retain ownership of new protein therapeutics, antibody drugs and small molecule targets discovered in this partnership. MPC will also provide the company with undisclosed financial support.
SC Biosciences, CuraGen's Japanese agent, helped execute this deal.
For more information, see the press release.